Does Higher Cost Buy Better Care?

Findings

1. No reliable positive correlation between cost and quality exists across the broad U.S. healthcare landscape.
2. Cost variance between providers is overwhelmingly driven by efficiency—how much care is delivered—not by unit price.
3. Physician practice style is the primary mechanism of efficiency variance.
4. Episode-based payment models have proven that cost reduction and quality maintenance are simultaneously achievable.
5. Existing episode programs have captured only a fraction of achievable savings because they are triggered by inpatient admission, not by diagnosis.
6. The episode of care—defined from diagnosis through recovery—is the unit of measurement and accountability most directly matched to the structure of the U.S. healthcare cost problem.

Abstract

Importance. It is widely assumed, by purchasers and patients alike, that paying more for health care buys better care—that a higher-priced hospital, a more expensive physician, or a more intensively treated region delivers higher quality. Cost is therefore frequently used as a proxy for quality, and “centers of excellence,” premium tiers, and reference-pricing programs are built on the premise that the two move together. Whether they do is an empirical question with large consequences for benefit design and provider selection.

Objective. To synthesize the published evidence on the association between health care cost (spending, hospital cost, and negotiated price) and quality of care, and to assess whether a definitive, generalizable correlation exists in either direction.

Evidence acquisition. Structured review of U.S. and international peer-reviewed studies from 1990 through 2025, anchored on three independent systematic reviews and supplemented by landmark primary studies that use the strongest available identification strategies—regional comparisons, natural experiments exploiting patient and physician migration, and within-market provider-level analyses. Studies were classified by the direction of the reported association (positive, negative, or none) and by the setting in which it was observed.

Findings. Across three systematic reviews spanning more than 100 studies, the association between cost and quality is inconsistent in both direction and magnitude. The largest U.S. review (61 studies) found 34% reporting a positive or mixed-positive association, 30% negative or mixed-negative, and 36% no association or a null result—an almost even three-way split. Two later reviews, one international and one European, reached the same conclusion of high heterogeneity with no dominant direction. The direction that does appear is context-dependent: higher spending and price are more often associated with better outcomes in acute, time-sensitive conditions (acute myocardial infarction, surgery, emergency care), and with no benefit or worse outcomes in chronic, elective, and supply-sensitive care, where most spending occurs.

Conclusions and relevance. There is no definitive, generalizable correlation between the cost of care and its quality. Cost is not a reliable signal of quality, and price in particular—the lever purchasers most often pull—shows essentially no relationship to quality at the provider level. Quality must therefore be measured directly rather than inferred from price, and benefit designs that steer patients toward lower-cost providers do not, on the weight of the evidence, sacrifice quality to do so.

1. Introduction

Few beliefs about health care are as durable, or as rarely tested, as the intuition that you get what you pay for. Patients routinely interpret a higher price or a more famous hospital as a marker of better care, and purchasers institutionalize the same assumption when they build premium provider tiers, route complex cases to designated centers, or treat a practice’s negotiated rate as a rough index of its standing. If cost and quality move together, then steering patients toward cheaper providers would mean steering them toward worse care, and the central tension in cost containment would be a genuine trade-off between the two.

The premise deserves scrutiny because so much rests on it. If, instead, cost and quality are only weakly and inconsistently related, then three conclusions follow. First, cost cannot serve as a shortcut for quality; the two must be measured separately. Second, programs that lower spending by steering toward efficient, lower-priced providers need not degrade quality—and may improve it where higher spending reflects overtreatment. Third, the value proposition in health care is not “pay more, get more” but the far less orderly reality that what is paid and what is delivered are governed by largely different forces.

This review asks a deliberately narrow question: across the published evidence, is there a definitive correlation between the cost of care and its quality? We treat “cost” in its three distinct senses—regional or per-capita spending, the cost a hospital incurs to deliver care, and the price a payer negotiates—because the literature treats them differently and they do not behave alike. We treat “quality” as the literature operationalizes it: validated process measures, risk-adjusted mortality and complications, readmissions, and patient-reported outcomes and experience. The aim is not to argue that quality is unimportant or that cheaper is always better, but to establish, on the evidence, whether price and spending tell a purchaser anything reliable about the quality of the care being bought.

2. Evidence and Approach

This is a structured narrative review rather than a de novo meta-analysis. The cost–quality literature is too heterogeneous in its definitions of cost, its quality measures, its units of analysis, and its identification strategies to support a single pooled effect size; indeed, that heterogeneity is itself a central finding. Rather than pool incommensurable estimates, we organize the evidence around its strongest pillars and assess the consistency of its direction.

Three elements structure the synthesis. First, we anchor on three independent systematic reviews—one U.S.-focused, one international, one European—each of which screened a large body of primary studies and classified them by the direction of association. These reviews provide the most defensible summary of the field because they aggregate findings without privileging any single result. Second, we examine landmark primary studies that use the strongest available designs to isolate a causal relationship: comparisons across regions with differing spending, natural experiments that exploit the migration of patients and physicians, and within-market analyses that compare providers serving similar populations. Third, we separate the evidence by clinical context—acute versus chronic, procedural versus condition-based—because the direction of any association turns out to depend on it.

We classify each body of evidence as showing a positive association (higher cost accompanies higher quality), a negative association (higher cost accompanies lower quality), or no reliable association. Throughout, we distinguish carefully between spending (how much care is delivered, and therefore how many dollars flow), hospital cost (the resource cost of producing care), and price (the negotiated rate per unit of service), because conflating them is the single most common source of confusion in this literature.

3. The Evidence

3.1 What the systematic reviews show: no dominant direction

The most authoritative summary of the field is also the most cited. Hussey, Wertheimer, and Mehrotra, searching three databases for U.S. studies published between 1990 and 2012, identified 61 studies that quantified the association between health care cost and quality. Their tally is the empirical heart of this question. Of the 61 studies, 21 (34%) reported a positive or mixed-positive association, 18 (30%) reported a negative or mixed-negative association, and 22 (36%) reported no association or a null or imprecise result. The evidence, in other words, splits almost evenly three ways. The authors concluded that the association between cost and quality is “inconsistent” in both direction and magnitude—a finding that, more than a decade on, remains the consensus characterization of the field.

Systematic review	Studies	Direction of association reported
Hussey et al., 2013 (U.S., 1990–2012)	61	34% positive/mixed-positive; 30% negative/mixed-negative; 36% none/null
Jamalabadi et al., 2020 (international, 1990–2019)	47	Highly heterogeneous; positive more likely with price (vs. cost) and process (vs. outcome) measures
Søgaard & Enemark, 2017 (Europe)	22	Positive, negative, two-directional, and null all present; no explanatory pattern found

Two subsequent systematic reviews, neither restricted to the United States, reach the same destination by different routes. Jamalabadi, Winter, and Schreyögg screened the literature through March 2019 and analyzed 47 studies of the relationship between hospital cost or price and quality. They described the findings as “highly heterogeneous,” and—importantly—identified the conditions under which a positive association is more likely to appear: when price or reimbursement is the cost measure rather than the hospital’s own cost; when quality is captured by process measures rather than outcomes; when the clinical focus is acute myocardial infarction, heart failure, or stroke rather than other conditions; and when the analysis uses more sophisticated methods to address confounding. The pattern is itself a finding: whether cost and quality appear to move together depends heavily on what one measures and how. Søgaard and Enemark, reviewing 22 European studies, found “positive, negative, two-directional and no association” all represented, and could not explain the inconsistency by diagnosis, procedure, quality measure, or model specification. Three reviews, three regions, one conclusion: no stable relationship.

3.2 The case for no association—or a negative one

The most influential evidence in this direction comes from the study of regional variation. Fisher and colleagues, in a pair of 2003 papers that shaped two decades of policy, compared Medicare beneficiaries in higher- and lower-spending regions of the United States. Regions in the highest spending quintile spent roughly 60% more per capita than those in the lowest, delivering more physician visits, more tests, more procedures, and more time in hospital. Yet beneficiaries in the higher-spending regions had no better survival, no better functional status, and no greater satisfaction with their care; on several measures they fared slightly worse. The additional spending bought more care, but not better health.

Subsequent work sharpened the point and, in places, tipped it negative. Baicker and Chandra found that states with higher Medicare spending delivered lower-quality care, a relationship they linked to a workforce mix tilted toward specialists and intensive services that crowd out more effective, lower-cost care. Sirovich and colleagues showed that physicians in higher-intensity regions did not perceive their care as better and were no more likely to follow evidence-based practice—the extra intensity reflected local practice style, not clinical need. Moving from regions to hospitals, Yasaitis and colleagues found that individual hospitals with higher spending intensity did not deliver measurably better quality, and Jha and colleagues, examining hospitals’ risk-adjusted costs directly, found no consistent relationship between cost and mortality and no evidence that low-cost providers delivered worse care. The recurring result across regions and hospitals alike is that spending more is not reliably associated with doing better.

The price-specific evidence is the most directly relevant to purchasers, because price is the lever they actually pull. Here the finding is strikingly clean. Roberts, Mehrotra, and McWilliams compared high-price and low-price physician practices in the same markets and found that they “do not differ significantly on care quality or efficiency.” A practice commanding a premium negotiated rate was, on the measured dimensions, no better than a cheaper one down the street. For the purchaser deciding whether a higher-priced provider is worth it, this is close to a direct answer: on average, the premium buys reputation and market leverage, not demonstrably better care.

3.3 The case for a positive association

Intellectual honesty—and defensibility before a clinical audience—requires giving the contrary evidence its full weight, because it is real and, in specific settings, persuasive. The strongest positive findings come from acute, time-sensitive care, where the marginal service can be the difference between life and death.

Romley, Jena, and Goldman examined inpatient mortality across 208 California hospitals for more than 2.5 million admissions in six major conditions and found that patients admitted to higher-spending hospitals had lower risk-adjusted inpatient mortality. The effect was meaningful and survived extensive risk adjustment. Doyle’s study is methodologically the most compelling on this side of the ledger: by studying patients who fall ill while traveling—visitors who become emergencies far from home and are effectively assigned to a local hospital at random with respect to its spending—he removed the selection problem that plagues observational comparisons and found that those treated in higher-spending areas had significantly lower mortality. When the design is strongest and the setting is acute, more spending can save lives.

This is consistent with the pattern the systematic reviews detected. Positive associations cluster precisely where Jamalabadi and colleagues said they would: in acute myocardial infarction, heart failure, and stroke—conditions in which timely, intensive, guideline-concordant intervention is decisive—and when the cost measure is price and the quality measure is a process of care. The positive evidence is not an artifact to be explained away; it is a real relationship confined to a definable slice of medicine. The error is to generalize from that slice to the whole.

3.4 Reconciling the contradiction: context governs direction

The apparent contradiction dissolves once the evidence is sorted by clinical context, and the reconciliation is the most useful product of this review. The relationship between cost and quality is not a single number but a function of the setting, and it changes sign across settings.

Setting / condition	Typical direction	Why
Acute, time-sensitive (AMI, stroke, surgery, emergencies)	Positive	Marginal intensive service is often decisive; more timely, guideline-concordant care improves survival
Chronic, elective, supply-sensitive (most condition care)	None or negative	Extra services reflect local practice style and capacity, not need; overtreatment adds risk without benefit
Price at the provider level (same market)	None	Negotiated price reflects market leverage and reputation, not measured quality

Three mechanisms explain the pattern. In acute care, the production function still has room on the upside: an additional catheterization performed quickly, an additional hour of skilled monitoring, can convert a death into a survival, so spending and outcomes move together. In chronic and elective care—where the majority of spending lives—the marginal service is far more likely to be supply-sensitive: ordered because the capacity exists and the practice style favors it, not because the patient’s condition demands it. There the extra spending buys tests, visits, and procedures that add cost and iatrogenic risk without adding health, which is why the association flattens to zero or turns negative. And price, as distinct from spending, is set by negotiation—by market concentration, brand, and bargaining power—none of which is quality, which is why provider price and provider quality are essentially uncorrelated.

Seen this way, the three systematic reviews and the conflicting primary studies are not in tension. They are sampling different regions of the same uneven landscape. A literature that draws heavily on acute conditions and process measures will report positive associations; one that draws on chronic care, outcomes, and regional spending will report null or negative ones. The honest summary is not that cost and quality are unrelated everywhere, but that no single, definitive correlation holds across the field—which is exactly what a purchaser needs to know before using price as a proxy for quality.

3.5 The asymmetry that matters for purchasers

For anyone designing benefits or selecting providers, the practically decisive finding is the one about price. Spending—how much care is delivered—has a defensible positive relationship to outcomes in acute medicine. But price—what a provider charges per unit—does not track quality even there. The provider-level evidence is consistent: high-price and low-price practices serving the same market deliver comparable quality, and high-cost hospitals are not reliably safer or more effective than low-cost ones. A purchaser who steers patients away from a high-priced provider toward a lower-priced one in the same market is, on the weight of the evidence, not trading quality for savings. This is the asymmetry that makes price-aware benefit design defensible on clinical grounds: the lever that lowers cost is largely orthogonal to the dimension that determines quality.

4. Discussion

The central conclusion is a negative one, and negatives are easy to overstate. So it is worth being precise about what the evidence does and does not support. It does not support the claim that quality is unrelated to everything a purchaser can see; structural features, volume, and validated outcome measures do distinguish providers. It does not support the claim that cheaper is always better; in acute care, higher spending can genuinely save lives. What it does support, with unusual consistency across three systematic reviews and the strongest primary studies, is that the cost of care—and especially its price—is not a dependable signal of its quality. The correlation that purchasers and patients assume to exist does not exist in any stable, generalizable form.

Three implications follow. First, quality must be measured directly. Because cost carries little reliable information about quality, the two cannot be collapsed into one. A provider’s price, prestige, or spending intensity is not a quality metric, and using it as one will mislead in a substantial share of cases. Validated process and outcome measures, risk-adjusted and reported at the level at which care is actually delivered, are the only defensible basis for quality comparison.

Second, lowering cost need not lower quality. The fear that cost containment necessarily degrades care assumes the very correlation the evidence fails to confirm. Where higher spending reflects supply-sensitive overtreatment—the larger share of the spending in chronic and elective care—reducing it can be neutral or even beneficial for patients, since unnecessary services carry their own risks. Steering toward efficient, lower-priced providers in the same market does not, on the evidence, sacrifice quality.

Third, the exceptions must be respected. The positive association in acute, time-sensitive care is real, and a responsible design does not apply a blunt low-cost rule to a patient mid-infarction. The appropriate posture is selective: aggressive about price and efficiency in the broad domain where they do not track quality, and protective of access and intensity in the narrow domain where they do. A framework that measures quality directly can make exactly that distinction, because it no longer has to use cost as a stand-in for what it cannot otherwise see.

None of this diminishes the role of the physician. The variation that drives cost is largely a matter of practice style and clinical judgment exercised under uncertainty, not of any provider charging too much for a known quantity of quality. The point is not that expensive clinicians are worse, but that expense, by itself, tells a purchaser nothing reliable about who is better—and that better information, not blunter incentives, is what the evidence calls for.

5. Limitations

Several limitations bound these conclusions. The underlying literature is observational in large part, and even the strongest natural experiments address particular settings—emergency patients far from home, migrants between regions—whose results may not generalize to elective, planned care. Quality is measured inconsistently across studies, ranging from a handful of process measures to risk-adjusted mortality, and the choice of measure demonstrably affects whether an association appears. Risk adjustment is imperfect, and residual confounding—sicker patients sorting to higher-spending providers—can mask or distort a true relationship in either direction. Much of the regional evidence is drawn from Medicare and may not translate directly to commercial populations, where price dynamics differ. Publication and measurement practices vary across the decades the reviews span. Finally, this is a structured narrative synthesis, not a pooled meta-analysis; it characterizes the consistency of the evidence’s direction rather than estimating a single effect size, a choice dictated by the heterogeneity that is itself the principal finding. None of these caveats overturns the central result—three systematic reviews independently fail to find a dominant direction—but they counsel against treating any single point estimate, positive or negative, as the last word.

6. Conclusion

The belief that higher cost buys better care is intuitive, widely held, and not supported by the evidence as a general proposition. Across three independent systematic reviews encompassing more than a hundred studies, the association between cost and quality is inconsistent in direction and magnitude, splitting nearly evenly among positive, negative, and null findings. The direction that does emerge is local to context: higher spending is associated with better outcomes in acute, time-sensitive care, and with no benefit or worse outcomes in the chronic and elective care where most spending occurs. Price, the lever purchasers most often use, shows essentially no relationship to quality at the provider level.

For those who design and pay for health benefits, the operative conclusion is therefore not that cheaper is better, but that cost is not a proxy for quality and must not be used as one. Quality has to be measured on its own terms. When it is, the apparent trade-off between lowering cost and protecting quality largely dissolves: a purchaser can steer toward efficient, lower-priced care across most of medicine without sacrificing quality, while preserving intensity in the acute settings where it demonstrably matters. The most durable path to value is not to pay more in the hope of getting more, but to measure quality directly, pay for it deliberately, and stop assuming that the two were ever reliably the same thing.

References

1. Hussey PS, Wertheimer S, Mehrotra A. The association between health care quality and cost: a systematic review. Ann Intern Med. 2013;158(1):27–34.

2. Jamalabadi S, Winter V, Schreyögg J. A systematic review of the association between hospital cost/price and the quality of care. Appl Health Econ Health Policy. 2020;18(5):625–639.

3. Søgaard R, Enemark U. The cost–quality relationship in European hospitals: a systematic review. J Health Serv Res Policy. 2017;22(2):126–133.

4. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138(4):273–287.

5. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med. 2003;138(4):288–298.

6. Baicker K, Chandra A. Medicare spending, the physician workforce, and beneficiaries’ quality of care. Health Aff (Millwood). 2004;23(Suppl 1):W4-184–W4-197.

7. Yasaitis L, Fisher ES, Skinner JS, Chandra A. Hospital quality and intensity of spending: is there an association? Health Aff (Millwood). 2009;28(4):w566–w572.

8. Sirovich BE, Gottlieb DJ, Welch HG, Fisher ES. Regional variations in health care intensity and physician perceptions of quality of care. Ann Intern Med. 2006;144(9):641–649.

9. Jha AK, Orav EJ, Dobson A, Book RA, Epstein AM. Measuring efficiency: the association of hospital costs and quality of care. Health Aff (Millwood). 2009;28(3):897–906.

10. Roberts ET, Mehrotra A, McWilliams JM. High-price and low-price physician practices do not differ significantly on care quality or efficiency. Health Aff (Millwood). 2017;36(5):855–864.

11. Romley JA, Jena AB, Goldman DP. Hospital spending and inpatient mortality: evidence from California. An observational study. Ann Intern Med. 2011;154(3):160–167.

12. Doyle JJ. Returns to local-area health care spending: evidence from health shocks to patients far from home. Am Econ J Appl Econ. 2011;3(3):221–243.